| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-06-0628 |
| P698 | PubMed publication ID | 17363505 |
| P50 | author | Edward K Geissler | Q114400579 |
| P2093 | author name string | Andreas Gaumann | |
| Ulrich Bolder | |||
| Wolfgang Dietmaier | |||
| Christian Moser | |||
| Hans J Schlitt | |||
| Marc H Dahlke | |||
| Gabriel Glockzin | |||
| Oliver Stoeltzing | |||
| Sven A Lang | |||
| Dagmar Klein | |||
| P433 | issue | 3 | |
| P304 | page(s) | 1123-1132 | |
| P577 | publication date | 2007-03-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo | |
| P478 | volume | 6 |
| Q33688498 | 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells |
| Q34989144 | 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2 |
| Q59048455 | A Novel Mechanism for Cross-Adaptation between Heat and Altitude Acclimation: The Role of Heat Shock Protein 90 |
| Q34472013 | A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair |
| Q37148194 | A novel therapeutic strategy for the treatment of glioma, combining chemical and molecular targeting of hsp90a |
| Q60304694 | A transcriptomics analysis of the Tbx5 paralogues in zebrafish |
| Q38130312 | Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales |
| Q39567800 | Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins |
| Q34852929 | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas |
| Q37090677 | Association of hsp90 to the hTERT promoter is necessary for hTERT expression in human oral cancer cells |
| Q36328446 | Custom RT-qPCR-array for glaucoma filtering surgery prognosis |
| Q33354649 | ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo |
| Q41900600 | Effect of non-anticoagulant N-desulfated heparin on basic fibroblast growth factor expression, angiogenesis, and metastasis of gastric carcinoma in vitro and in vivo |
| Q53091400 | Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. |
| Q54720598 | Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection. |
| Q41470003 | Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling |
| Q37442676 | Gastric cancer in the era of molecularly targeted agents: current drug development strategies |
| Q38050092 | Genomic dysregulation in gastric tumors |
| Q34845463 | HIF-1α is essential for effective PMN bacterial killing, antimicrobial peptide production and apoptosis in Pseudomonas aeruginosa keratitis |
| Q36729440 | HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo |
| Q42936269 | Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus |
| Q33407026 | Heat Shock Protein-27, -60 and -90 expression in gastric cancer: association with clinicopathological variables and patient survival |
| Q35437393 | Heat shock protein 90 inhibition by 17-DMAG attenuates abdominal aortic aneurysm formation in mice |
| Q43162731 | Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis |
| Q37442623 | Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance |
| Q37308085 | Heat shock protein 90 is involved in regulation of hypoxia-driven proliferation of embryonic neural stem/progenitor cells |
| Q37639711 | Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy |
| Q34702116 | High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer |
| Q51762437 | High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. |
| Q37772399 | Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. |
| Q37081037 | Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin |
| Q37731561 | Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma |
| Q35780464 | Immune microenvironment as a factor of breast cancer progression. |
| Q36795358 | Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer |
| Q36741693 | Inhibition of gastric tumor growth by a novel Hsp90 inhibitor |
| Q28265268 | Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer |
| Q34957090 | MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors |
| Q37962816 | Molecular targeted agents for gastric and gastroesophageal junction cancer |
| Q36680209 | Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab |
| Q24672758 | Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility |
| Q40031313 | Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor |
| Q49387452 | Prognostic role of HSPs in human gastrointestinal cancer: a systematic review and meta-analysis |
| Q50042580 | Pyruvate kinase M2 promotes pancreatic ductal adenocarcinoma invasion and metastasis through phosphorylation and stabilization of PAK2 protein. |
| Q35106935 | Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention |
| Q38365290 | Receptor tyrosine kinase inhibitors: Are they real tumor killers? |
| Q37293806 | Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90 |
| Q37596178 | Role of the tumor microenvironment in the pathogenesis of gastric carcinoma |
| Q35863874 | Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? |
| Q33703311 | Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer |
| Q37882456 | Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II. |
| Q33576827 | Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells. |
| Q36347106 | Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer |
| Q38909587 | The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model |
| Q34407501 | The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells |
| Q37516972 | The role of heat shock proteins in gastrointestinal diseases |
| Q47694405 | Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives. |
| Q41347745 | Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. |
Search more.